Advanced search for available technology

  Username(email)             Password
  (Same as The Knowledge Vine if you are a Vine user)This service is provided free by UMIP^®

          

Latest IP offers

A new generation of small peptides (6-12mers) with potent in vitro and in vivo activity against influenza A viruses     |       Fuel cell technology that converts Urine / Urea / Ammonia to energy and clean water - low cost viable alternative to H2     |       A method of assessing efficiency of internal combustion engines      |       Software for viewwing, manipulating and interpreting LiDAR (ground penetrating radar) data      |       A s/w programmable CMOS chip in which an image processor is integrated within each pixel of the image sensor     |

Latest Tech Requests

Reduction of sodium andamp; saturated fats in foodstuffs     |       Increased sound absorption for nonwoven materials     |       Prevention of flavour volatile loss during cooking     |       Do you use Yet2, Ninesigma or Innocentive? Why?     |       Post your tech requests on IP Net for free     |

Overview       Browse IP offers       Browse tech requests       Advanced Search       Testimonials       FAQs       Encouraging open innovation       What makes this different?       Our Sponsors & Partners

Email this IP record To email address From email address Email subject Email message IP Net technology offering #IP0000870 Title Rapid test for Hepatitis C Virus drug efficacy What the technology is An assay that allows the rapid identification of drugs to treat Hepatitis C virus. What it does This is the first facile system that allows the growth of all HCV strains in vitro and the rapid efficacy of novel protease inhibitor drugs to be assessed. The technology can be used to assess HCV drug resistance and to determine the most appropriate treatment regime for infected individuals. Possible applications Diagnostic Kit of improved patient outcomes; Drug discovery; Diagnostic phenotypic assay for drug selectivity; Research tools Perceived UNIQUE ADVANTAGES Simple and cost effective method to simultaneously in vitro test drug efficacy for all strains of Hepatitis C; Improved patient outcomes; Cost savings for health providers by reducing use of inappropriate drugs Further Information such as stage of development A patent has been filed on this technology. The University of Edinburgh is seeking industrial partners to help commercialise this technology via a licensing and collaborative research agreement. Link to further info Organisation marketing this The University of Edinburgh Country Location United Kingdom Reference number 2370 Contact name Alex Proudfoot Contact phone number Search the IP Net database   Advanced search View other IP Net Technologies that may have synergy with this Send a message to this IP provider Message Your name Your organisation Your email address